Despite that we did not find differences in IL-6 among NSCLC patients classified according to anti-PD-(L)1 response, in other cancers, such as melanoma and breast cancer, IL-6 levels at baseline have been correlated with rapid disease progression [44,45]. Here, CD274 is linked to melanoma.